Regeneron Therapeutics faces a class action lawsuit alleging it misled investors about the viability of its Phase III trial combining Fianlimab and Libtayo for advanced melanoma. The lawsuit claims Regeneron made overly positive statements while hiding that the trial's statistical assumptions were flawed and that the treatment was not outperforming standard therapies. Stock prices dropped significantly after Regeneron disclosed changes to the trial and later announced it failed to meet its primary endpoint. Investors who purchased Regeneron shares between August 2025 and May 2026 may be eligible to join the lawsuit, which is being handled by Robbins LLP.
Regeneron Pharmaceuticals ended August positively as its Dupixent sales surged to €5.15 billion in Q2, up 23.6% sequentially, offsetting declines in Eylea sales due to biosimilar competition. Additionally, the FDA approved Pasatru on August 19 for tr...
Regeneron Pharmaceuticals has chosen Veeva Vault CRM globally to enhance its commercial operations by generating Commercial Evidence through AI-powered field engagement. This platform will help Regeneron's commercial teams access critical information...
